Recent insights regarding the molecular basis of myeloproliferative neoplasms

Recent insights regarding the molecular basis of myeloproliferative neoplasms

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders characterized by the overproduction of mature blood cells that have an increased risk of thrombosis and progression to acute myeloid leukemia. Next-generation sequencing studies have provided key insights regarding the...

Full description

Bibliographic Details
Main Authors:	Mi-Ae Jang, Chul Won Choi
Format:	Article
Language:	English
Published:	The Korean Association of Internal Medicine 2020-01-01
Series:	The Korean Journal of Internal Medicine
Subjects:	mutation thrombocythemia, essential polycythemia vera primary myelofibrosis
Online Access:	http://www.kjim.org/upload/pdf/kjim-2019-317.pdf

Similar Items

The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
by: Sung-Yong Kim, et al.
Published: (2021-01-01)

NK Cells in Myeloproliferative Neoplasms (MPN)
by: Erin Naismith, et al.
Published: (2021-08-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
by: Tarinee Rungjirajittranon, et al.
Published: (2019-02-01)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
by: Moysés Antonio Porto-Soares, et al.
Published: (2020-07-01)

Risks of Solid and Lymphoid Malignancies in Patients with Myeloproliferative Neoplasms: Clinical Implications
by: Mette Brabrand, et al.
Published: (2020-10-01)

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
by: Jonathan Heppner, et al.
Published: (2019-05-01)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
by: Lucia Catani, et al.
Published: (2021-09-01)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
by: Loscocco GG, et al.
Published: (2020-12-01)

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative
by: Olteanu Ariela Ligia, et al.
Published: (2016-09-01)

Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition
by: Leslie Padrnos, et al.
Published: (2020-11-01)

Disease-Specific Derangement of Circulating Endocannabinoids and <i>N</i>-Acylethanolamines in Myeloproliferative Neoplasms
by: Dorian Forte, et al.
Published: (2020-05-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
by: Alessandro Allegra, et al.
Published: (2020-10-01)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
by: Paulo Vidal Campregher, et al.
Published: (2012-01-01)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
by: Jingbo Yu, et al.
Published: (2018-04-01)

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
by: Mihnea-Alexandru Găman, et al.
Published: (2021-07-01)

Myeloproliferative neoplasms (MPNs) – Part 2: A nursing guide to managing the symptom burden of MPNs
by: Sabrina Fowlkes, et al.
Published: (2018-11-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
by: Hans C. Hasselbalch, et al.
Published: (2020-08-01)

Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
by: Razan Hayati Zulkeflee, et al.
Published: (2021-07-01)

Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance
by: Saeid Shahrabi, et al.
Published: (2018-10-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
by: Giuseppe G. Loscocco, et al.
Published: (2021-08-01)

The Role of Genotypes That Modify the Toxicity of Chemical Mutagens in the Risk for Myeloproliferative Neoplasms
by: Carol Ann Gross-Davis, et al.
Published: (2015-02-01)

Philadelphia-negative chronic myeloproliferative neoplasms
by: Rosane Isabel Bittencourt, et al.
Published: (2012-01-01)

Aetiology of Myeloproliferative Neoplasms
by: Mary Frances McMullin, et al.
Published: (2020-07-01)

WT1 Gene Overexpression in Differential Diagnosis of Ph-negative Myeloproliferative Disorders
by: EG Lomaia, et al.
Published: (2019-05-01)

The Role of Inflammation and Inflammasome in Myeloproliferative Disease
by: Lucia Longhitano, et al.
Published: (2020-07-01)

Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm
by: Ik-Chan Song, et al.
Published: (2021-09-01)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2018-12-01)

Calreticulin Mutations in Myeloproliferative Neoplasms
by: Noa Lavi
Published: (2014-10-01)

Biology of Myeloproliferative Malignancies
by: AL Melikyan, et al.
Published: (2016-07-01)

Clinical and laboratory presentations of Janus Kinase II-positive patients in Saudi population
by: H Malhan, et al.
Published: (2014-01-01)

Evaluation of JAK2V617F Mutation Prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: B Bahar, et al.
Published: (2009-11-01)

Evaluation of JAK2V617F mutation prevalence in Myeloproliferative Neoplasm by AS-RT-PCR
by: H Ghafari, et al.
Published: (2009-09-01)

Trends and Inpatient Outcomes of Venous Thromboembolism-Related Admissions in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
by: Vatsala Katiyar, et al.
Published: (2019-07-01)

Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera
by: Federico Lussana, et al.
Published: (2017-02-01)

Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses
by: Vibe Skov
Published: (2020-08-01)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01)

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL
by: Vincenzo Accurso, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_7drli9vidscrmpba7qr2vu2dpc